Share on StockTwits

Oramed Pharmaceuticals (NASDAQ:ORMP)‘s stock had its “buy” rating restated by analysts at Aegis in a research report issued to clients and investors on Tuesday.

Oramed Pharmaceuticals (NASDAQ:ORMP) opened at 9.62 on Tuesday. Oramed Pharmaceuticals has a 1-year low of $6.12 and a 1-year high of $31.73. The stock has a 50-day moving average of $9.17 and a 200-day moving average of $13.2. The company’s market cap is $95.6 million.

Oramed Pharmaceuticals Inc is a development-stage pharmaceutical company. The Company is engaged in the research and development of pharmaceutical solutions, including an orally ingestible insulin capsule or tablet to be used for the treatment of individuals with diabetes, use of orally ingestible capsules, tablets or pills for delivery of other polypeptides.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.